Braveheart Bio (BRVE) Surges 66% in IPO Debut as Investors Embrace Precision Cardiovascular Medicine
Braveheart Bio, Inc. (NASDAQ: BRVE) delivered one of the strongest biotechnology IPO performances of...
Braveheart Bio (NASDAQ: BRVE) has filed to raise approximately $300 million through an initial publi...